Cytological responses of the pituitary (rostral pars distalis) and immunoreactive corticotropin-releasing factor (CRF) in the goldfish treated with dopamine antagonists.
The in vivo effects of three dopamine (DA) antagonists on the cytology of the rostral pars distalis (RPD) were investigated in young goldfish (Carassius auratus L.). Pimozide, sulpiride, and domperidone were injected for 5 (low dose, Experiment I) and 7 days (higher dose, Experiment II). Cytological and immunocytochemical techniques using antisera to (1-24) ACTH and (1-39) ACTH, human beta-thyrotropin (TSH beta), and synthetic (1-41) CRF were applied to pituitary and brain sections. Cytometrical studies showed that the three drugs induced similar quantitative changes in the cells of the RPD. Prolactin (PRL)-secreting cell hypertrophy was significant in Experiment II, whereas the nuclear enlargement was significant in both experiments. The numbers of cytoplasmic granules were similar in control and treated goldfish. Thyrotropic (TSH) cells and their nuclei were significantly enlarged in both experiments; their content in immunoreactive TSH was not clearly modified. Corticotropic (ACTH) cells showed significant nuclear and cellular hypertrophy, and labeled granules were often concentrated along the cell membrane. The amount of immunoreactive CRF present in the rostral neurohypophysial ramifications was reduced in the majority of treated fish. Solvent-injected controls showed no significant changes in the RPD. These results suggest that DA inhibits PRL cell activity in goldfish. TSH and ACTH cells appear stimulated by DA-receptor blockers, although differential effects on synthesis and release cannot be evaluated in in vivo experiments. A release of corticotropin-releasing factor may be involved in the ACTH cell stimulation. These data are compared with those obtained in other vertebrates.
Olivereau
M
M
Laboratoire de Physiologie, Institut Océanographique, Paris, France.
Olivereau
J M
JM
Lambert
J F
JF
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism*; D003530:Cyprinidae / Q000502:physiology*; D004294:Domperidone / Q000494:pharmacology*; D004298:Dopamine / Q000031:analogs & derivatives; D018492:Dopamine Antagonists; D006054:Goldfish / Q000502:physiology*; D007124:Immunoenzyme Techniques; D010868:Pimozide / Q000494:pharmacology*; D010903:Pituitary Gland, Anterior / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D013469:Sulpiride / Q000494:pharmacology*; D013972:Thyrotropin / Q000378:metabolism
D018492:Dopamine Antagonists; D010868:Pimozide; D004294:Domperidone; D013469:Sulpiride; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013972:Thyrotropin; D003346:Corticotropin-Releasing Hormone; D004298:Dopamine